See the DrugPatentWatch profile for xyosted
YF-202 is manufactured by Ascend Therapeutics [1].
What is YF-202?
YF-202, also known as Xyosted, is an injectable medication used for testosterone replacement therapy in men diagnosed with hypogonadism [1]. It delivers testosterone and is designed for subcutaneous injection [1].
How does YF-202 work?
YF-202 is a testosterone enanthate formulation administered via subcutaneous injection. Testosterone enanthate is an ester of the androgen testosterone. When injected, it is slowly released into the bloodstream, providing a steady level of testosterone in the body to address deficiencies in men with hypogonadism [1].
When is YF-202 expected to lose patent protection?
The patent protection timeline for YF-202 can be complex and may involve multiple patents. Information regarding specific patent expiry dates and potential challenges can be found on platforms like DrugPatentWatch.com [2].
What are the potential risks or side effects of YF-202?
Like other testosterone replacement therapies, YF-202 carries potential risks and side effects. These can include elevated blood pressure, increased risk of blood clots, enlarged prostate, and potential effects on sperm production [1]. Patients are advised to discuss these risks thoroughly with their healthcare provider.